<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03485911</url>
  </required_header>
  <id_info>
    <org_study_id>BCX7353-302</org_study_id>
    <nct_id>NCT03485911</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE</brief_title>
  <acronym>APeX-2</acronym>
  <official_title>A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioCryst Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioCryst Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to
      evaluate the efficacy and safety of oral BCX7353 in preventing acute angioedema attacks in
      patients with Type I and Type II HAE.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: The rate of investigator-confirmed HAE attacks during dosing in the entire 24-week treatment period (Day 1 to Day 168)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Change from baseline in Angioedema Quality of Life questionnaire at Week 24 (total score)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in Quality of Life, on a 1-100 scale, where higher scores indicate more impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Proportion of days with angioedema symptoms through 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Rate of investigator-confirmed HAE attacks during dosing in the effective treatment period (beginning on Day 8 through 24 weeks)</measure>
    <time_frame>Day 8 to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: The safety of oral BCX7353 capsules</measure>
    <time_frame>24 weeks</time_frame>
    <description>The number and percentage of subjects with treatment-emergent adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Rate of investigator-confirmed HAE attacks</measure>
    <time_frame>Weeks 24-48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Durability of response (attack rate trend over time)</measure>
    <time_frame>Weeks 24-48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Durability in Angioedema Quality of Life questionnaire score</measure>
    <time_frame>Weeks 24-48</time_frame>
    <description>Change in Quality of Life, on a 1-100 scale, where higher scores indicate more impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Proportion of days with angioedema symptoms</measure>
    <time_frame>Weeks 24-48</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Hereditary Angioedema</condition>
  <condition>HAE</condition>
  <arm_group>
    <arm_group_label>BCX7353 110 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCX7353 administered as oral capsules once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCX7353 150 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCX7353 administered as oral capsules once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo administered as oral capsules once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCX7353 capsules</intervention_name>
    <description>BCX7353 oral capsules administered once daily</description>
    <arm_group_label>BCX7353 110 mg once daily</arm_group_label>
    <arm_group_label>BCX7353 150 mg once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Matching oral capsules administered once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  A clinical diagnosis of hereditary angioedema Type 1 or Type 2, defined as having a
             C1-INH functional level and a C4 level below the lower limit of the normal (LLN)
             reference range, as assessed during the Screening period.

          -  Subject weight of ≥ 40 kg

          -  Access to and ability to use one or more acute medications approved by the relevant
             competent authority for the treatment of acute attacks of HAE

          -  Subjects must be medically appropriate for on-demand treatment as the sole medicinal
             management for their HAE during the study.

          -  Subjects must have a specified number of investigator-confirmed attacks during the
             run-in period of a maximum of 56 days from the Screening visit.

          -  Acceptable effective contraception

          -  Written informed consent

        Key Exclusion Criteria:

          -  Pregnancy or breast-feeding

          -  Any clinically significant medical condition or medical history that, in the opinion
             of the Investigator or Sponsor, would interfere with the subject's safety or ability
             to participate in the study

          -  Any laboratory parameter abnormality that, in the opinion of the Investigator, is
             clinically significant and relevant for this study

          -  Severe hypersensitivity to multiple medicinal products or severe hypersensitivity/
             anaphylaxis with unclear etiology

          -  Use of C1-INH within 14 days or use of androgens or tranexamic acid within 28 days
             prior to the Screening visit for prophylaxis of HAE attacks, or initiation of these
             drugs during the study

          -  Current participation in any other investigational drug study or received another
             investigational drug within 30 days of the Screening visit

          -  Prior enrollment in a BCX7353 study
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Zuraw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC San Diego School of Medicine, US HAE Angioedema Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study director</last_name>
    <phone>+1 919 859 1302</phone>
    <email>clinicaltrials@biocryst.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Study center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Center</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study center</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study center</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study center</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55446</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study center</name>
      <address>
        <city>Belleville</city>
        <state>New Jersey</state>
        <zip>07109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Center</name>
      <address>
        <city>Fair Lawn</city>
        <state>New Jersey</state>
        <zip>07410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study center</name>
      <address>
        <city>Piscataway</city>
        <state>New Jersey</state>
        <zip>08854</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study center</name>
      <address>
        <city>Clackamas</city>
        <state>Oregon</state>
        <zip>97015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Center</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1G 6C6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4V 1R2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Center</name>
      <address>
        <city>Québec</city>
        <zip>G1V 4W2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Center</name>
      <address>
        <city>Sângeorgiu de Mureș</city>
        <state>Jud. Mureș</state>
        <zip>547530</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Center</name>
      <address>
        <city>London</city>
        <zip>E1 2ES</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Center</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Center</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Center</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Romania</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2018</study_first_submitted>
  <study_first_submitted_qc>March 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2018</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BCX7353</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

